InterMune (FRA:IUX) Days Payable : 225.30 (As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is InterMune Days Payable?

InterMune's average Accounts Payable for the three months ended in Jun. 2014 was €10.49 Mil. InterMune's Cost of Goods Sold for the three months ended in Jun. 2014 was €4.25 Mil. Hence, InterMune's Days Payable for the three months ended in Jun. 2014 was 225.30.

The historical rank and industry rank for InterMune's Days Payable or its related term are showing as below:

FRA:IUX' s Days Payable Range Over the Past 10 Years
Min: 0 Med: 0 Max: 350.4
Current: 350.4

During the past 13 years, InterMune's highest Days Payable was 350.40. The lowest was 0.00. And the median was 0.00.

FRA:IUX's Days Payable is not ranked
in the Biotechnology industry.
Industry Median: 134.39 vs FRA:IUX: 350.40

InterMune's Days Payable declined from Jun. 2013 (542.76) to Jun. 2014 (225.30). It may suggest that InterMune accelerated paying its suppliers.

InterMune Days Payable Historical Data

The historical data trend for InterMune's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InterMune Days Payable Chart

InterMune Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Days Payable

Get a 7-Day Free Trial

863.19

2,340.20

592.14

640.05

InterMune Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Days Payable	Get a 7-Day Free Trial															542.76	323.55	349.15	421.28	225.30

Competitive Comparison of InterMune's Days Payable

For the Biotechnology subindustry, InterMune's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InterMune's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InterMune's Days Payable distribution charts can be found below:

* The bar in red indicates where InterMune's Days Payable falls into.

InterMune Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

InterMune's Days Payable for the fiscal year that ended in Dec. 2013 is calculated as

	Days Payable (A: Dec. 2013 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2012 )	+	Accounts Payable (A: Dec. 2013 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2013 )	*	Days in Period
=	( (14.392	+	12.248)	/	2 )	/	7.596	*	365
=	13.32					/	7.596	*	365
=	640.05

InterMune's Days Payable for the quarter that ended in Jun. 2014 is calculated as:

	Days Payable (Q: Jun. 2014 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Mar. 2014 )	+	Accounts Payable (Q: Jun. 2014 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2014 )	*	Days in Period
=	( (10.217	+	10.755)	/	2 )	/	4.247	*	365 / 4
=	10.486					/	4.247	*	365 / 4
=	225.30

InterMune Days Payable Related Terms

Thank you for viewing the detailed overview of InterMune's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

InterMune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.intermune.com

InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

InterMune Headlines

No Headlines